Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS) a pioneering force in artificial intelligence for healthcare education, has unveiled two innovative solutions aimed to transform medical education: AI Patient and AI Doctor in a Pocket. These offerings are integrated into the company’s Medical Education Suite (MES), which supports the comprehensive educational journey of healthcare professionals from basic patient interactions to complex diagnostic assessments.
The MES has been conceivedsystem is crafted to streamline the administrative load on faculty, enrich the educational experience for students, and support students in their the preparation for key clinical exams. thePrincipally, the Objective Structured Clinical Examination (OSCE) — a critical exam used in 57 countries to assess the clinical and practical skills of healthcare students. With a market opportunityuser base spanning 300 medical schools and 900 nursing schools and 230,000 students in the U.S. alone, Treatment.com AI is expanding its impact by discussing potential partnerships with institutions in the UK and Canada.
The newly launched AI Patient and AI Doctor in a Pocket are subscription-based SaaS solutions that leverage the company's proprietary Global Library of Medicine (GLM) to enhance the readiness of students and healthcare professionals for exams and real-world medical scenarios. These tools aim to provide continuous support from education to practice, ensuring a seamless transition for healthcare providers.
Why AI?
Artificial intelligence (AI) is rapidly becoming a transformative force in various sectors. According to Grand View Research, Healthcare is at the forefront of this technological revolution, with the healthcare IT market size estimated at US$663 billion in 2023.
Grand View continued to say, "Increasing usage of smartphones, a growing demand for remote patient monitoring for improved out-of-hospital care, technologically advanced healthcare IT infrastructure, and an increase in the number of initiatives and investments supporting eHealth and digital are driving overall market growth."
The significance of AI in healthcare extends to personalized medicine, where AI algorithms help tailor treatments to individual patients based on their unique health data. This personalized approach is not only more effective but also minimizes the risk of adverse reactions, enhancing patient safety. As the healthcare industry continues to evolve, AI technologies are expected to play a pivotal role in managing the increasing complexity of medical diagnostics, treatment planning, and patient management. This integration of AI promises to significantly improve outcomes for patients and efficiency for healthcare providers, marking a critical evolution in the healthcare sector that aligns with broader technological advancements in society.
According to Statista, the artificial intelligence (AI) healthcare market, which was valued at US$11 billion in 2021, is forecasted to reach US$187 billion by 2030. This substantial growth indicates that significant transformations are likely to continue in the operations of medical providers, hospitals, pharmaceutical companies, biotechnology firms, and other entities within the healthcare sector.
Catalysts
The upcoming developments for Treatment.com AI represent significant catalysts that could influence the company's trajectory and valuation. With their new SaaS (Software as a Service) solutions, AI Patient and AI Doctor in a Pocket, set to launch in the second half of 2024, they look to enhance the training and clinical decision-making capabilities of healthcare professionals and students. The successful rollout of these subscription-based services could lead towill propel increased revenue streams and market penetration for Treatment.com AI.
Moreover, the proprietary Global Library of Medicine (GLM) underpins the company’s offerings, providing a robust database supported by hundreds of credentialed clinicians worldwide.
This comprehensive resource not only enhances the company's product offerings but also establishes its credibility and utility in a competitive market. The ongoing development and expansion of the GLM are crucial for maintaining the company's competitive edge and appeal to new and existing customers.
Expert Opinions
In a February posting, Technical Analyst Clive Maund wrote about the company's potential, saying, "Treatment.com AI Inc. is a company that should have a very bright future as it has been pioneering the development of an AI healthcare platform using AI and advanced machine learning technologies that has the potential to revolutionize healthcare due to the streamlining of healthcare provision and the massive cost savings across the industry that should result."
Streetwise Ownership Overview*
Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS)
Maund continued, "The company is already in partnership with the Mayo Clinic and ...the University of Minnesota Medical School and is in discussion with another 52 organizations."
Ownership and Share Structure
According to Reuters, two insiders own 13.12%, or 4.87 million (4.87M) shares, of Treatment.com AI. They are Chief Medical Officer, Chairman and Director Dr. Kevin Peterson with 10.35% or 3.84M shares and John Fraser with 2.76% or 1.03M shares.
Retail investors own the remaining 86.88%. There are no institutional investors currently.
The company has 38.0839.22 million outstanding shares and 33.2 million free-float traded shares.
Its market cap is CA$23.38 million, and its 52-week trading range is CA$0.10 to CA$1.20 per share.
| Want to be the first to know about interesting Healthcare Services investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- In addition, Treatment.com AI has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
- James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
Contributing Author Disclosures:
- Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing this article. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in this content accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed.
Clivemaund.com Disclosures
The above represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks can only be construed as a solicitation to buy and sell securities when they are subject to the prior approval and endorsement of a Registered Securities Advisor operating in accordance with the appropriate regulations in your area of jurisdiction.
